US Appeals Court rejects 10x Genomics’ appeal and finds patents asserted against Parse Biosciences invalid
SEATTLE — August 19, 2026 — Parse Biosciences, a leading provider of accessible and scalable single-cell sequencing solutions, today announced that the US Court of Appeals for the Federal Circuit rejected 10x Genomics’ appeal to overturn prior decisions made by the Patent Trial and Appeal Board that invalidated 10x’s patents asserted against Parse, further reinforcing Parse’s ability to drive ongoing innovation in the single-cell space.
Parse welcomes the Federal Circuit’s affirmance of the invalidation of 10x’s patents. Parse will continue to steadfastly pursue its mission of helping scientists use single-cell sequencing to expand the body of knowledge in human health and science.